Abstract: A system and method are provided for creating an image including quantified flow within vessels of a subject. The method includes providing a single-sweep, three-dimensional (3D) image volume acquired from a subject during a single pass of a computed tomography (CT) imaging system as the subject receives a dose of a contrast agent and determining a phase shift corresponding to pulsatile contrast in vessels within the single-sweep, 3D image volume. The method further includes quantifying a flow through the vessels within the single-sweep, 3D image volume using the phase shift and generating a report including indicating flow through the vessels within the 3D image volume.

Abstract: A transcranial scanning device and method of use is disclosed. The transcranial scanning device is for identifying a neurologic-injury-mechanism and comprises a sensing wand comprising a transducer that produces and receives sound waves. The sensing wand is passed over a head of a patent with cerebral malaria, and sound waves reflect off of blood cells in blood vessels in the head of the patient creating an output sound wave responsive to a blood flow of the patient. The output sound wave is received by the transducer. An output screen coupled to the sensing wand, displays in real time an output waveform corresponding to the output sound wave, wherein the output waveform is indicative of one or more symptoms of cerebral malaria, and wherein said symptoms identify one or more neurologic-injury-mechanism occurring within the patient.

Abstract: The specification generally relates to compounds of Formula (I): (I) and pharmaceutically acceptable salts thereof, where R, A1, A2 and A3 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent DNA-PK mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating DNA-PK mediated disease, including cancer, using such compounds and salts.

Abstract: A process for producing a chalcogen-containing compound semiconductor includes providing at least one substrate coated with a precursor for the chalcogen-containing compound semiconductor in a process chamber; heat treating the at least one coated substrate in the process chamber, wherein during a heat treatment, a gas atmosphere comprising at least one gaseous chalcogen compound is provided in the process chamber; removing the gas atmosphere present after the heat treatment of the at least one coated substrate as a waste gas from the process chamber; cooling the waste gas in a gas processor, wherein a plurality of gaseous chalcogen compounds-present in the waste gas after the heat treatment of the at least one coated substrate are separated in time and space from one another from the waste gas by respective conversion into a liquid or solid form. Further provided is a device designed to carry out the process.

Abstract: Embodiments provide for predicting rowhammer attack vulnerability of one or more memory cells of a direct random access memory (DRAM) chip, the DRAM chip including a plurality of memory cells. An example method, determines, for each memory cell of a subset of memory cells of the plurality of memory cells, a leakage time t, a resistance of intrinsic leakage RL based at least in part on the leakage time t, an activation time of an adjacent aggressor row to flip a bit in the memory cell, a resistance of coupling leaking RSW based at least in part on the activation time, and a toggling count. The method identifies, based at least in part on one or more of the RSW, RL, or toggling count, whether the direct random memory access (DRAM) chip is vulnerable to a rowhammer attack.

Abstract: Provided are embodiments of para-substituted 1,1-dialkyl-4-phenylpiperazin-1-ium iodides advantageous for modulating inflammation that have been synthesized and their electrophysiology activities for ?9, ?9?10, and ?7 nAChRs compared. The para position contained alkyl or aryl amides, or heterocyclic isosteres for the amide, and the alkyl groups were varied at the ammonium piperazine nitrogen to see if compensatory changes in size at this position of the molecule impacted function. The compounds were characterized with two-electrode voltage-clamp measurements on Xenopus oocytes expressing nAChRs. General, the compounds were more potent for ?9-containing receptors than for ?7, and the majority were either full or strong partial agonists for ?9-containing nAChR.

Abstract: The present embodiments provide for substituted triazolylpyridine derivative compounds, and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for modulating the activity of histone demethylase enzymes. Additionally, the subject compounds and compositions are useful for the treatment of cancer or other neoplastic diseases, or maladies associated with abnormal histone demethylase activity. Accordingly, the substituted triazolylpyridine derivative compounds described herein are useful in methods and medicaments for treating cancer.

Abstract: The present disclosure provides wireless power transfer systems and methods. One such system includes a transmitter comprising a transmitter coil coupled to a power source and a transmitter metasurface slab positioned on a front side of the transmitter coil that is configured to amplify and focus a magnetic field generated by the transmitter coil towards a receiver in a non-contact manner. In such a system, the receiver comprises a receiver coil coupled to a load and a receiver metasurface slab positioned on a front side of the receiver coil configured to amplify and focus a magnetic field generated by the transmitter coil towards the receiver coil in a non-contact manner. Other systems and methods are also provided.

Abstract: Provided is a novel bacterial strain Bacteroides vulgatus MGM001 (Bacteroides vulgatus MGM001) and its use. The LPS from the strain of the subject matter has cytotoxicity weaker than the conventional ones and shows synergistic effect on the inhibition of biofilm formation when used in combination with LTA.

Abstract: Devices such as multiports comprising connection ports with associated securing features and methods for making the same are disclosed. In one embodiment, the device comprises a shell, at least one connection port, at least one securing feature passageway, and at least one securing feature. The at least one connection port is disposed on the multiport with the at least one connection port comprising an optical connector opening extending from an outer surface of the multiport to a cavity of the multiport and defining a connection port passageway. The at least one securing feature is associated with the connection port passageway, and the at least one securing feature is disposed within a portion of the at least one securing feature passageway.

Abstract: A method for coding image information includes generating prediction information by predicting information on a current coding unit, and determining whether the information on the current coding unit is the same as the prediction information. When the information on the current coding unit is the same as the prediction information, a flag indicating that the information on the current coding unit is the same as the prediction information is coded and transmitted. When the information on the current coding unit is not the same as the prediction information, a flag indicating that the information on the current coding unit is not the same as the prediction information and the information on the current coding unit are coded and transmitted. At the generating of the prediction information, the prediction information is generated by using the information on the coding unit neighboring to the current coding unit.

Abstract: A method and system for managing health care patient record data including identifying and conveying recordation and temporal inconsistencies in health care patient data pertaining to chronic illnesses. An embodiment of the present invention includes identifying a first health care encounter date on which a chronic illness is recorded in a patient's digital health care data and determining if the chronic illness was recorded in the patient's digital health care data for each subsequent health care encounter. Some embodiments also identify the stage of the chronic illness at each encounter to determine if and how the condition of the chronic illness has changed. Some embodiments generate alerts to inform users when a preexisting chronic illness is not subsequently identified and/or if the subsequent diagnosis of the chronic illness indicates that the condition of the chronic illness has changed by some predetermined amount.

Abstract: Methods to manufacture volume transmission diffraction grating (quasi-Bragg gratings) and volume transmission diffraction gratings made by those methods.

Abstract: A controller of a machine determines jointly a sequence of control inputs defining a state trajectory of the machine and a desired knowledge of the environment by solving a multivariable constrained optimization of a model of dynamics of the machine relating the state trajectory with the sequence of control inputs subject to a constraint on admissible values of the states and the control inputs defined based on the desired knowledge of the surrounding environment represented by the state of the environment and the uncertainty of the state of the environment determined from the measurements of the environment. In such a manner, the controller performs joint but imbalance optimization of the control inputs and the sensing instructions to the sensor for learning the environment.

Abstract: The present invention is related to the use of HMGB1 antagonists such as K883 in the treatment and/or prevention and/or inhibition of severe sepsis in mammals, e.g., humans, and pharmaceutical compositions for the same comprising HMGB1 antagonists in an effective amount to treat and/or prevent and/or inhibit this condition.

Abstract: The present disclosure belongs to the technical field of African swine fever (ASF) treatment, in particular to use of a compound aprepitant in prevention or treatment of the ASF. In the present disclosure, it is found that the compound aprepitant can significantly inhibit replication of an African swine fever virus (ASFV); in addition, it is found that the aprepitant inhibits transcription and protein expression of D1133L, and reduces transcription and protein expression levels of p30 and p72, preventing virus invasion on host cells. Therefore, the compound aprepitant can be used to inhibit early and late infection of the ASFV. Accordingly, the compound aprepitant can be used to prevent or treat the ASF.

Abstract: A system jointly estimates states of GNSS receivers moving in a region using measurements of a Global Navigation Satellite System (GNSS). The system clusters the GNSS receivers into different clusters subject to a constraint on an upper bound on each cluster and executes a set of probabilistic filters corresponding to the set of clusters to estimate the states of GNSS receivers in each cluster. Each probabilistic filter estimates the states of the GNSS receivers in a corresponding cluster by fusing the GNSS data collected from the GNSS receivers in the cluster to jointly reduce an estimation error of each of the GNSS receivers in the cluster. The DES updates the cluster assignments based on a measure of estimation error in the states of different GNSS receivers in different clusters.

Abstract: A pharmaceutical composition comprising an active agent that causes reduction of the level of systemic immunosuppression in an individual for use in treating a disease, disorder, condition or injury of the CNS that does not include the autoimmune neuroinflammatory disease, relapsing-remitting multiple sclerosis (RRMS), is provided. The pharmaceutical composition is for administration by a dosage regimen comprising at least two courses of therapy, each course of therapy comprising in sequence a treatment session followed by an interval session.

Abstract: Disclosed are methods and probiotic compositions for the treatment of a metabolic disease or disorder such as, e.g., obesity, type 2 diabetes, or fatty liver. In some embodiments, heat-inactivated Parabacteroides goldsteinii is enterically administered to a subject, such as a human patient, to treat the metabolic disease or disorder or to promote the development of warm microbiota to treat the metabolic disease or disorder. In some aspects, spermine or spermidine may be administered to a subject or used in vitro to promote the growth of microbiota that can be used for the treatment of a metabolic disease or disorder.